Best of Oncology Podcast Series

In this episode, we'll listen to Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Peter Ellis discuss the important trials presented at ESMO 2019.

00:01 Introduction of the Best of Oncology Podcast

00:22 Introduction of Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Peter Ellis

01:33 LBA5 FLAURA OS

13:47 IMpower110 Study

19:06 LBA4 Checkmate 227

28:13 Small cell lung cancer - IMpower133, CASPIAN PD-L1

In this episode, we'll listen to Dr. Sunil Verma, Dr. Hope Rugo and Dr. Peter Schmid discuss the important trials presented at ASCO 2019.

01:01 - Her 2 Positive Breast Cancer

18:59 - Hormone Receptor Positive

37:37 - Triple Negative Breast Cancer and Immunotherapy

In this episode, we'll listen to Dr. Scott Berry, Dr. Marc Peeters and Dr. Sharlene Gill, discuss the important trials presented at ASCO 2019.

08:20 - Apact Trial

16:35 - Phase 3 Trial of 1st Line Chemo vs Pembrolizumab vs Chemo + Pembrolizumab for Metastatic Gastric CA

24:15 - Phase 3 Trial of 2nd Line Pembrolizumab vs Placebo for HCC

30:26 - ABC-06

35:35 - IDEA Study (High Risk Stage 2 Patients)

46:19 - Foxtrot Trial

In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best of San Antonio Breast Cancer Symposium in Toronto, where they shared their thoughts on the most impactful data released in Triple Negative Breast Cancer at the flagship meeting a few weeks earlier.